Arsenol Oral Solution(Jacobson Pharma )

三氧化二砷口服制剂 (雅各臣科研制药)

Report date: 2026/04/16 20:00:17

Base Information

Drug NameArsenol Oral Solution(Jacobson Pharma )
Drug Alias NameARSENOLSDK-001
ClassificationSmall molecules
Mechanisms of ActionImmunostimulantsApoptosis stimulantsDNA synthesis inhibitors +[4] 
TargetsThioredoxin reductase
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Promyelocytic, Acute +[4] 
Global Approved IndicationsLeukemia, Promyelocytic, Acute
Approved Indications in ChinaLeukemia, Promyelocytic, Acute
Original Approved Country/TerritoryHong Kong
Original Approved Date2010/06/28
Country/TerritorySingaporeHong Kong
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesThe University Of Hong KongJacobson Pharma Corporation Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAmerican Unicorn Laboratories LtdSDK Therapeutics LlcThe University Of Hong Kong +[4] 
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Promyelocytic, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A